MHB018A Treatment in Patients With Active Thyroid Eye Disease

Summary

The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.

Timeline

Start

2025-07-22

Primary completion

2026-07-31

Completion

2027-07-31

Drugs

Indications